MRSA Nasal Treatment could break resistance problem

Link: MRSA Is A Slow Moving Hurricane That Cannot Be Averted Says Infection Expert.

For those covering this news and stories on new approaches on eradicating MRSA, NovaBay Pharmaceuticals is making available Dr. Ron Najafi, CEO of NovaBay. Dr. Najafi believes the issue of MRSA is similar to a slow moving hurricane, gathering strength and resistance as it spreads. "Once the 'superbug' hits a community or hospital," asks Dr. Najafi, "are populations ready to deal with it?" That is why Dr. Najafi believes a different approach is necessary in treating the rapidly increasing infectious microbes that have become resistant to our current slate of drugs. Dr. Najafi and the research team at NovaBay are currently working on a compound, NVC-422, which has shown promise combating numerous pathogens including MRSA. NovaBay believes that the colonization of S. aureus takes place primarily in the nose and on the skin. The damp and dark qualities of nasal tissue create an ideal breeding ground for the bacteria to grow and spread. AgaNase™, NovaBay's formulation of NVC-422 for nasal applications, is unique in that it is an anti-infective, though not a conventional antibiotic. Topically applied to the lower nasal passage to eliminate colonization of S. aureus, including MRSA, AgaNase rapidly destroys a range of pathogens that include bacteria, yeast, and viruses. Because AgaNase is a chlorine-based analog of molecules produced by white blood cells, it is believed that bacteria and viruses are unlikely to develop resistance to this treatment.

Comments

[Karen Ricotta]

Where can I purchase AgaNasa? I called a pharmacy which did not carry it and tried to order but did not come up in their
data base.
Thanks